Live Webinar90 min
Beyond Liver Biopsy: The Evolving Role of Noninvasive Tests in MASLD, MetALD, and ALD
Your seat
Saturday, January 30
01:00 PM UTC · 90 min
Format
Online
Price
Free
Join link opens 10 minutes before the conference.
About the Speaker
Hepatology, Gastroenterology, Transplant HepatologyWinston Dunn, MD
MD, FAASLD
Professor of Medicine · University of Kansas Medical Center · USA
Dr. Winston Dunn, MD, FAASLD, is Professor of Medicine in the Division of Gastroenterology at the University of Kansas Medical Center. He is an internationally recognized hepatologist with expertise in metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), advanced liver fibrosis, and noninvasive assessment of liver disease. His research focuses on clinical epidemiology, predictive modeling, machine learning, and novel approaches to risk stratification in chronic liver disease. He has led multiple clinical trials investigating emerging therapies for steatotic liver disease and has authored more than 80 peer-reviewed publications. Dr. Dunn is a Fellow of the American Association for the Study of Liver Diseases (FAASLD), with a strong commitment to advancing precision hepatology and translating research findings into clinical practice.
About This Conference
Explore the evolving role of noninvasive tests (NITs) in the diagnosis, fibrosis assessment, risk stratification, and clinical management of metabolic dysfunction-associated steatotic liver disease (MASLD), MetALD, and alcohol-associated liver disease (ALD).
